Back to Main

Healthcare Stocks Ending Higher; Myriad Genetics Back Near Day's High On Strong Results for Melanoma Test

By: MT Newswires
Posted: 10/14/2013 3:52:00 PM
Referenced Stocks: MYGN

Top Healthcare Stocks

JNJ +0.04%

PFE +2.02%

ABT +0.53%

MRK -0.96%

AMGN +0.16%

Healthcare stocks are mostly higher this afternoon with the NYSE Healthcare Sector Index adding 0.5% and shares of healthcare companies in the S&P 500 advancing just over 0.6% as a group.

In company news, Myriad Genetics, Inc. ( MYGN ) is up 5% to $23.90, retracing its path to an intra-day high of $23.98 and the molecular diagnostic company saying results from a verification study showed its myPath Melanoma test effectively differentiated malignant melanoma from benign skin lesions.

The verification study evaluated a 23-gene panel designed to differentiate malignant melanoma from benign skin lesions. The myPath Melanoma test demonstrated high sensitivity of 89% and specificity of 93% at differentiating malignant melanoma from benign skin lesions.

In other sector news,

(+) ATRS, The company's Otrexup injection for rheumatoid arthritis was approved by the U.S. Food and Drug Administration.

(-) CNDO, Said its TSO drug candidate to treat Crohn's disease failed to meet its primary endpoints during Phase II testing.